Results 161 to 170 of about 105,036 (275)

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

Arthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti, Inmaculada C. Penadés, Irina Nikishina, Ivan Foeldvari, Alberto J. Spindler, Anna Kozlova, Nadina Rubio‐Pérez, Pierre Quartier, Zbigniew Żuber, Raul Barria, Daniel Clemente, Gabriel V. Cornejo, Katherine Marzan, Nancy Liu, Christine Xu, Stephen DiMartino, Angeliki Giannelou, Fei Cao‐Ghoul, Bolanle Akinlade, Lydie Baret‐Cormel   +19 more
wiley   +1 more source

A Qualitative Analysis of Patient Perspectives and Preferences in Lupus Management to Guide Lupus Guidelines Development

Arthritis Care &Research, EarlyView.
Objective A patient‐centered approach for chronic disease management, including systemic lupus erythematosus (SLE), aligns treatment with patients’ values and preferences, leading to improved outcomes. This paper summarizes how patient experiences, perspectives, and priorities informed the American College of Rheumatology (ACR) 2024 Lupus Nephritis (LN)
Shivani Garg, Izzy Hartel, Lisa R. Sammaritano, Anca Askanase, Bonnie L. Bermas, Maria Dall'Era, Alí Duarte‐García, Victoria P. Werth, Brad Rovin, Reem A. Mustafa, Amy S. Turner, Bené Williams, Brian L. Ung, Hiya Bhavsar, Monique C. Gore‐Massy, Nahirannette Pulido, Natacha Guerrero, Natalie M. Smith, Wambui Machua, Linda T. Hiraki, Mary Beth Son   +20 more
wiley   +1 more source

US market entry by Spanish pharmaceutical firms [PDF]

This work explores the factors that spur firms’ propensity to enter in international markets. Among the whole population of Spanish firms active in the pharmaceutical sector (over the period 1995-2004), we identify those firms that have entered the US ...
Ester Martínez-Ros, Fabrizio Cesaroni, Marco S. Giarratana   +2 more
core  

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, EarlyView.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; ClinicalTrials.gov identifier ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) Network investigators   +14 more
wiley   +1 more source

HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing-Based Assays With Immunohistochemistry. [PDF]

JCO Precis Oncol
Nagamine M, Fujisawa T, Sakamoto N, Nakamura Y, Kadowaki S, Ueno M, Boku S, Komatsu Y, Oki E, Makiyama A, Nonomura N, Morizane C, Watari H, Okano S, Iwata H, Namikawa K, Hatanaka Y, Hatanaka KC, Taguchi K, Spetzler D, Radovich M, Magee D, Yoshino T, Oberley M, Kuwata T.   +24 more
europepmc   +1 more source

Addressing Economic Insecurities Can Improve Patient‐Reported Outcomes in Lupus

Arthritis Care &Research, Accepted Article.
Background Economic insecurities, such as food, housing, transportation, and financial challenges, are modifiable risk factors and influence patient‐reported outcomes (PROs) in systemic lupus erythematosus (SLE). We examined: 1) associations between economic insecurities and PROs; 2) the impact of screening and addressing economic insecurities during ...
Jay Patel, Tripti Singh, Meredith Ingersoll, Shelby Gomez, Amanda Weber, Sarah E. Panzer, Sancia Ferguson, Christie M. Bartels, Shivani Garg   +8 more
wiley   +1 more source

The impact of patent activity on idiosyncratic volatility in U.S. pharmaceutical companies. [PDF]

PLoS One
Atilgan E, Türkmen Ceylan FB, Doruk ÖT, Ertuğrul HM, Barak AY.   +4 more
europepmc   +1 more source

Immune Checkpoint Inhibitor Related Myositis and Associated Triad Overlap Syndrome

Arthritis Care &Research, Accepted Article.
Objective Immune checkpoint inhibitor (ICI) myositis is a rare but highly morbid condition, particularly with the ICI myositis triad syndrome of myositis, myocarditis, and myasthenia gravis. We report the clinical characteristics of ICI myositis and all‐cause mortality in these patients.
Selene Rubino, Grant W Cannon, Brian C Sauer, Jorge Rojas, Gregory J Stoddard, Gary A Kunkel, Jessica A. Walsh, Bryant R England, Joshua F Baker, Tawnie J Braaten   +9 more
wiley   +1 more source

Patent Landscape of Fiber-Based Fabrication Technologies for Functional Biomaterials: Electrospinning, Forcespinning^® and Melt Electrowriting in Tissue Engineering and Drug Delivery (2020 to 2024). [PDF]

J Funct Biomater
Sattler AM, Rodriguez-Salvador M, Vazquez-Armendariz J, Tejeda Alejandre R.   +3 more
europepmc   +1 more source

Effect of Implementing a Dashboard with or without a Best Practice Alert on HLA‐B*58:01 Testing Rates among Allopurinol Users at VA Medical Centers

Arthritis Care &Research, Accepted Article.
Objective The American College of Rheumatology recommends HLA‐B*58:01 allele testing before the initiation of allopurinol, specifically among Asian and Black/African American patients, due to their increased risk for severe hypersensitivity reactions.
Abimbola Fadairo‐Azinge, Gabriela Schmajuk, Sristi Sharma, Colleen P. Flanagan, Sara Faghihi‐Kashani, Ning Zhang, Mary A. Whooley   +6 more
wiley   +1 more source